Skip to main content
  1. Right Decisions
  2. Back
  3. Dermatology pathways
  4. Hyperhidrosis
Announcements and latest updates

Right Decision Service newsletter: March 2024

Welcome to the Right Decision Service (RDS) newsletter for March 2024. Please forward this newsletter to others who may be interested. They can contact olivia.graham@nhs.scot to be added to the circulation list.

Promotion and communication resources

Promotional flyers are now available in the Learning and Support area of RDS:

What is RDS and what impact does it have? (infographic)

General RDS flyer

Being a partner in my care: Realistic medicine app for citizens

Managing medicines for patients and carers app

Home care decisions app

Child protection app (South Lanarkshire HSCP)

All except the infographic are also available as editable Word versions. Please contact his.decisionsupport@nhs.scot  if you would like Word versions.  

Redesign and improvements to RDS

Search and browse improvements are progressing well and the plan is still to release these in mid-May.  The first stages of work on archiving and version control are complete. User stories (requirements) are being defined for:

  • Deep linking to individual toolkit URLs/QR codes
  • Translating content from a structured Word document directly into RDS
  • Capability to review and edit changes made to shared content

New feature requests

These have all been compiled and effort estimated. Once the redesign work is complete, these will be prioritised in line with the remaining budget. We expect this to take place around late June.

Evaluation

A big thank you to all of you who have completed our Impact and Value questionnaire. The data from this will be really helpful in informing the first draft of the business case for long term provision of the RDS. This will be reviewed by the National Advisory Board for RDS later this month.

We welcome further responses. If you haven’t yet completed the survey, please follow this link, and please encourage other RDS toolkit leads and users to do so.

New toolkits

A few examples of toolkits published to live in the last month:

 

Toolkits in development

Some of the toolkits the RDS team are currently working on:

  • Updates to the Respiratory prescribing guidance and Manage Medicines for patients and carers toolkits
  • Respiratory Managed Clinical Network Pathways
  • Child abuse pathways in NHS Tayside
  • Patient information leaflet collection in NHS Borders
  • Referral management toolkit for NHS Borders
  • NHS Lothian – Infectious diseases; Acute oncology guidelines; Royal Infirmary of Edinburgh Emergency Care.

Please contact his.decisionsupport@nhs.scot if you would like to learn more about a toolkit. The RDS team will put you in touch with the relevant toolkit lead.

Learning opportunities

The RDS Learning working group is progressing with developing training resources for editors, and intend to have resources to share by end of June. This includes resources for:

  • Each stage of the development journey for RDS toolkits – Scoping to Implementation/Evaluation and Maintenance.
  • RDS content governance.
  • Core functionality – learning bytes.

 

Editor webinars

Just a reminder that we are offering webinars for existing and potential new editors on the following dates:

  • Wednesday 10 April 3.30-4.30 pm
  • Thursday 18 April 12-1 pm

 

To book for one of these webinars, please complete the registration form at https://forms.office.com/e/eGjKqNVjeF

Quality audit

Many thanks to all of you who have met with me recently to complete or clarify your responses to the quality audit survey at the end of last year.  Work to complete the quality audit for all toolkits published on RDS prior to November last year will continue for the next few months.

Implementation projects

The RDS team is now working with Moray HSCP to evaluate impact of the new RDS toolkit “Preventing progress of diabetes”  (https://preventdiabetes.scot.nhs.uk ) to support people at high risk of diabetes type 2 and those who are candidates for remission. We are looking at the impact of use of the app with SMS prompts on people’s readiness for lifestyle change over an 8 week period. This includes comparing impact in people who have a call with a dietitian in addition to using the app to people who only use the app.

If you have any questions about the content of this newsletter, please contact us on his.decisionsupport@nhs.scot.

With kind regards

Right Decision Service team

Healthcare Improvement Scotland

 

Hyperhidrosis

Warning

Hyperhidrosis is uncontrollable excessive sweating that occurs at rest, regardless of temperature. In the localized type, the most frequent sites are the palms, soles and axillae. If the history is less typical, e.g. night sweats or if the patient is unwell, there could be a secondary cause.

Secondary hyperhidrosis may be caused by an underlying medical condition and/or as a side effect of a medication or procedure. Underlying medical and/or drug causes for generalised hyperhidrosis should be considered - https://cks.nice.org.uk/topics/hyperhidrosis/diagnosis/assessment/. Hyperhidrosis can be categorized by area of involvement — local versus generalized. The guidance below refers to primary idiopathic hyperhidrosis.

Treatment/ therapy

Mild: A score of 1 or 2 indicates mild or moderate hyperhidrosis. See hyperhidrosis disease severity scale in clinical resources box.

Self-care management strategies  

Primary axillary hyperhidrosis: 

  • Commercial antiperspirant rather than deodorant. 
  • Use emollient washes, rather than soap-based products 
  • Avoid tight clothing and man-made fabrics 

Primary Plantar Hyperhidrosis: 

  • Alternate footwear 
  • Moisture wicking-socks, change twice daily 
  • Avoid occlusive footwear such as boots-encourage leather shoes 

Primary focal hyperhidrosis: 

  • 20% aluminium chloride hexahydrate over the counter preparations such as roll-on antiperspirants and spray.  
  • Apply at night just before sleep to skin of the axillae, feet, or hands every 1–2 days as tolerated, until symptoms improve, then use as required. Wash off in the morning. 
  • For craniofacial hyperhidrosis, consider antiperspirant wipes (aluminium chloride) for application to the face (off-label use). 

If skin irritation occurs with aluminium salt preparations, prescribe hydrocortisone 1% cream to be applied once daily for up to two weeks. Also advise soap substitute and to reduce frequency of application until symptoms resolve. 

Moderate: A score of 2 or 3 indicates moderate hyperhidrosis. See hyperhidrosis disease severity scale in clinical resources box. 

Oral and topical therapy 

  • Higher strength aluminium salts (up to 50%). 
  • Topical glutaraldehyde or formaldehyde may be used. 
  • Topical glycopyrrolate may be useful for primary craniofacial hyperhidrosis (off-label indication) although is availability is usually within a secondary care setting. 
  • Oral anti-muscarinics such as oxybutynin and glycopyrronium bromide. Beware anti-muscarinic side effects.  

Oral antimuscarinics decrease sweat secretion.  

  • Oxybutynin (standard release): 5mg OD initially, then increase to twice daily. Unlicenced indication.  
  • Propantheline: 15mg TDS one hour before meals. Licenced. Dose could be titrated up to maximum of 120mg/day. 

Patients should be counselled with regards to anti-muscarinic side effects. 

 

 Iontophoresis therapy  

  • Recommended for palms and soles. Axillary treatment is impractical. If unsuccessful, glycopyrronium bromide (an anti-muscarinic agent) may be added to the water. Long term maintenance required.  
  • Iontophoresis machines can be rented/purchased and information regarding this is available on the international hyperhidrosis society website (link below) 

 

Severe: A score of 3 or 4 indicates severe hyperhidrosis.  See hyperhidrosis disease severity scale in clinical resources box. 

Botulinum A Toxin: 

  • Largely used for axillary hyperhidrosis 
  • Can be used for palms, soles, craniofacial hyperhidrosis but treatment is painful in these areas, limiting use. Effects last 6-9 months. 

Surgery  

  • Localized sweat gland resection may be carried out for small areas of axillary hyperhidrosis.  
  • Endoscopic thoracic sympathectomy (ETS) should only be considered when all other options are ineffective or not tolerated.  
  • Complications include compensatory hyperhidrosis elsewhere on the body (very common), pneumothorax (common, gustatory sweating (common), atelectasis, significant bleeding.  

Please note surgical approaches are rarely utilised due to the potential risks involved. 

 

Referral Management

Mild: A score of 1 or 2 indicates mild or moderate hyperhidrosis. See hyperhidrosis disease severity scale in clinical resources box. 

Manage in primary care using self-care measures and topical advice. 

See NICE guidance below: 

Refer to the dermatologist to consider specialist management if self-care and topical drug treatments are ineffective/not tolerated. Individual funding requests may be required for certain treatments e.g. Botulinum A Toxin and local availability varies.  

Moderate: A score of 2 or 3 indicates moderate hyperhidrosis. See hyperhidrosis disease severity scale in clinical resources box. 

Manage in primary care with oral and topical therapies.  

Refer to secondary care or consultant-led community service for iontophoresis/ Botulinum toxin (if commissioned locally). 

Severe: A score of 3 or 4 indicates severe hyperhidrosis. See hyperhidrosis disease severity scale in clinical resources box.

Refer to secondary care or consultant-led community service for iontophoresis and Botox (if commissioned). 

Availability of surgical intervention varies locally and may require individual funding requests. 

 

Clinical tips

  • In the context of generalised hyperhidrosis, consider screening for underlying medical causes  
  • Drug-induced causes of generalised hyperhidrosis include beta blockers, SSRIs, tricyclic antidepressants and opiates. 
  • After a successful trial of iontophoresis, patients may be advised to purchase their own device for long-term maintenance. 

Patient information resources

1. Hyperhidrosis BAD patient information leaflet 

2. NHS information leaflet: Excessive sweating (hyperhidrosis) 

3. Hyperhidrosis UK Support Group leaflet 

4. NHS Inform- Hyperhidrosis 

ICD search categories

Epidermal/Appendageal 

ICD11 code - EE00 

Editorial Information

Last reviewed: 09/06/2023

Next review date: 09/06/2025

Author(s): Adapted from the BAD Referral Guidelines.

Version: BAD 1

Co-Author(s): Publisher: Centre for Sustainable Delivery, Scottish Dermatological Society.

Approved By: Scottish Dermatological Society